ECOMPASS Meta-Analysis about efficacy of Cerebrolysin® in stroke
An increasing number of patients worldwide suffering from residual stroke. Many of them struggle with significant motor impairments. Spasticity and weakness are the most common limitations.
During the early recovery phase after stroke the brain is most receptive to modifications by rehabilitation. Cerebrolysin® has shown to promote neuroplasticity (neuronal sprouting, synaptogenesis, neurogenesis) even 8 days after the start of therapy.
In the evaluation of the ECOMPASS Meta-Analysis, a combination of rehabilitation therapy and Cerebrolysin®, represents an effective approach to enhance neurorecovery after stroke, proven by:
- Improving FMA-T and FMA-UL results within 90 days
- Clear evidence in TDI data of fractional anisotropy
This therapy reflects the clinical reality of stroke and clearly demonstrates that this treatment concept improves the health of patients which leads to:
- Improvement of motor recovery
- Enhancement of patient mobility
- Preventing the degeneration of the neuronal tissue
- Protection from haemorrhagic events
The full article of ECOMPASS Meta-Analysis can be found here.